Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Johnson & Johnson Innovation – JJDC

Founders Bruce Rosengard Chris Picariello Paul Stoffels Scott Orchard Seema Kumar Sue Hohenleitner

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 82
Average round size
info
The average size of a deal this fund participated in
$49M
Portfolio companies 59
Rounds per year 1.61
Lead investments 13
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.28
Exits 6
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Therapeutics
Summary

The leading representative office of defined VC is situated in the Cambridge. The company was established in North America in United States. Johnson & Johnson Innovation u2013 JJDC appeared to be a CVC structure as part of the corporation.

The increased amount of exits for fund were in 2018. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. This Johnson & Johnson Innovation u2013 JJDC works on 23 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Johnson & Johnson Innovation u2013 JJDC, startups are often financed by Wildcat Capital Management, Johnson & Johnson Development Corporation, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are Wildcat Capital Management, Whittier Ventures, VSP Global. In the next rounds fund is usually obtained by dRx Capital, Lux Capital, Lightstone Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Memebox, Fusion Pharmaceuticals, X-Vax Technology We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Johnson & Johnson Innovation – JJDC:
Typical Co-investors
Johnson & Johnson Innovation – JJDC is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Johnson & Johnson Innovation – JJDC:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bank One Chicago, Illinois, United States
Birk Venture Norway, Oslo
Delta Dental Illinois, Oak Brook, United States
Equilibrium Capital California, San Francisco, United States
Frog Capital England, London, United Kingdom
Harmony Medical -
ICICI Prudential Mutual Fund India, Maharashtra, Mumbai
Inlign Wealth -
Ironside Ventures Massachusetts, United States, West Newton
Macquarie Infrastructure Partners Australia, New South Wales, Sydney
McDonnell Ventures -
Peak Capital Partners Provo, United States, Utah
Shenzhen Yizan Investment Management China, Guangdong, Shenzhen
TR Capital China, Hong Kong, Hong Kong Island
ULan Network -
Upshift Partners California, San Francisco, United States
VENTA GROUP -
Venture Center India, Maharashtra, Pune
Xinhu Holding -
Yamanashi Chugin Management Consulting Japan, Kofu, Yamanashi Prefecture

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Accent Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$75M23 Jan 2024 Lexington, Kentucky, United States

Aro Biotherapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$41M28 Nov 2023 Philadelphia, Pennsylvania, United States

On Target Laboratories

Biotechnology
Life Science
Medical
$30M16 Nov 2023 Illinois, United States

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Rapport Therapeutics

Biotechnology
Health Care
Life Science
Medical
$150M23 Aug 2023 Boston, Massachusetts, United States

CirCode

Biotechnology
Life Science
Medical
15 Aug 2023 Shanghai, Shanghai, China

Astraveus

Biotechnology
$19M27 Jun 2023 Paris, Ile-de-France, France

Solenic Medical

Health Care
Medical
Medical Device
$5M20 Jun 2023 College Station, Texas, United States

Rapport Therapeutics

Biotechnology
Health Care
Life Science
Medical
$100M07 Mar 2023 Boston, Massachusetts, United States
News
Visus Therapeutics Raises $20M in Funding

– Visus Therapeutics from Seattle develops innovative ophthalmic therapies to improve vision for people around the world.
– The company raised $20m in funding.
– The round was led by LSP in Amsterdam with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors.
– The new investment will be used to advance its clinical and commercial efforts for lead asset BRIMOCHOL under investigation for presbyopia as well as new research and development activities in its drug development pipeline.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Johnson & Johnson Innovation – JJDC?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 82
Average round size 49M
Rounds per year 1.61
Peak activity year 2020
Lead investments 13
Follow on index 0.28
Exits 6
Group Appearance index 0.93

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Accent Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$75M23 Jan 2024 Lexington, Kentucky, United States

Aro Biotherapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$41M28 Nov 2023 Philadelphia, Pennsylvania, United States

On Target Laboratories

Biotechnology
Life Science
Medical
$30M16 Nov 2023 Illinois, United States

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Rapport Therapeutics

Biotechnology
Health Care
Life Science
Medical
$150M23 Aug 2023 Boston, Massachusetts, United States

CirCode

Biotechnology
Life Science
Medical
15 Aug 2023 Shanghai, Shanghai, China

Astraveus

Biotechnology
$19M27 Jun 2023 Paris, Ile-de-France, France

Solenic Medical

Health Care
Medical
Medical Device
$5M20 Jun 2023 College Station, Texas, United States

Rapport Therapeutics

Biotechnology
Health Care
Life Science
Medical
$100M07 Mar 2023 Boston, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: